The Washington Post points out the benefits of gender transition therapy for minors in a new editorial puberty blockers It has not been scientifically proven.
"Treatment results that look impressive in small groups tend to disappear when larger groups are studied," the Washington Post editorial board said. write in one piece Sunday's headline read: "Looking to science, not law, for real answers in adolescent gender medicine."
The Washington Post is responding to the public debate Supreme Court Tennessee’s Puberty Blocker Ban in United States v. Schemetti . Experts believe the Supreme Court's decision in the case could set a precedent that could affect laws around the country regarding gender reassignment treatment for children.
“That’s why the U.S. Food and Drug Administration often requires large, randomized controlled drug trials: to ensure that encouraging preliminary results are more than just statistical noise,” the Washington Post writes.
"The court's ruling will have a significant impact on the 24 states that have imposed these restrictions, but it will not resolve a crux of the debate over pediatric gender medicine: whether the treatments save lives, as plaintiffs say, or whether, as some global health authorities say, That has been established, the evidence is too weak to conclude they are beneficial, and the risks are not fully understood," the editorial board argued.
it tells a story this year recognized california doctor A study that found puberty blockers did not improve mental health was withheld for fear the findings would be "weaponized" by critics of transgender health care.
“Medical progress will not be possible unless null or negative results are announced as promptly as positive results,” the committee wrote. “The failure to adequately evaluate these treatments gives Tennessee reason to be concerned about them and legal space to restrict them. .We have serious reservations when states make decisions about minors’ health care rather than leaving it to parents.
The Post also noted the debate over puberty blockers in Europe, with "multiple European health authorities" reviewing the scientific evidence for their use among minors and "concluded that the certainty was 'very low' , 'lacking' and 'limited by methodological weaknesses. "Last week, the UK banned the use of puberty blockers indefinitely over safety concerns.
"However the court rules, however, the federal government should provide the missing evidence at the heart of the dispute," the Washington Post wrote. "Randomized trials are best, although difficult to achieve now because children placed in the control group may drop out and seek blockers and hormones elsewhere. Nonetheless, Congress should fund new studies that are as rigorous as possible and Overseen by scientists in non-randomized trials.
United States v. Schemetti Centered on Tennessee Law The state bans sex reassignment treatment for minors. The law, passed in March 2023, also targets health care providers in Tennessee who continue to provide gender reassignment treatment to transgender minors, exposing them to fines, lawsuits and other liabilities.
Fox News' Breanne Deppisch and Peter Pinedo contributed to this report.